Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : The collaboration will help Gracell leverage Lonza's worldwide integrated services and expertise in CAR-T cell therapy manufacturing. Gracell is advancing its innovative CAR-T pipeline globally for difficult-to-treat cancers, including its lead program f...
Product Name : GC012F
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 31, 2021
Lead Product(s) : Elasomeran
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Moderna Announces New Drug Substance Production Agreement with Lonza in the Netherlands
Details : The agreement will establish a new production line at Lonza’s Geleen site in the Netherlands, contributing to the supply of an additional 300 million doses of Moderna’s updated booster variant vaccine candidate, Spikevax, if authorized, per year, at ...
Product Name : Spikevax
Product Type : Vaccine
Upfront Cash : Undisclosed
February 06, 2021
Lead Product(s) : Elasomeran
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
